Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$6.05M+173%
Alkermes logo
AlkermesALKS
$68.02M+21.4%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$35.4M-10.4%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.56B+66.3%
Enterprise value$4.9B+88.3%
P/E18.2×-7.2×
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemMarch 31, 2026December 31, 2025
Long-term debt, less current portion486290
Accrued litigation settlement expenses, noncurrent4152
Operating lease liabilities, noncurrent1422
Other noncurrent liabilities2121
Total liabilities$1,341$1,300
Commitments and contingencies (Note 12)
Stockholders' deficit
Common stock, par value $0.001 per share (2026) and $0.50 per share (2025). Issued shares: 122 (2026) and 125 (2025)—62

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s other non-current liabilities?
Indivior Pharmaceuticals, Inc. (INDV) reported other non-current liabilities of $21M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s other non-current liabilities changed year-over-year?
Indivior Pharmaceuticals, Inc.'s other non-current liabilities increased by 23.5% year-over-year, from $17M to $21M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s other non-current liabilities?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s other non-current liabilities has grown at a -17.7% compound annual growth rate (CAGR), from $31M to $21M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Indivior Pharmaceuticals, Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude